Table 1.
Characteristics of the 91 Study Patients.*
| Characteristic | Value | Reference Range |
|---|---|---|
| Demographic features | ||
| Median age (IQR) — yr | ||
| At presentation | 48 (36–59) | — |
| At end of follow-up | 54 (38–62) | — |
| Sex — no. (%) | ||
| Male | 46 (51) | — |
| Female | 45 (49) | — |
| Race — no. (%)† | ||
| White | 86 (95) | — |
| Black | 5 (5) | — |
| Medical history | ||
| Median duration of follow-up (range) — yr | 3 (0–6) | — |
| General infectious complications — no. (%) | 63 (69) | — |
| Autoimmune clinical manifestations — no. (%)‡ | 33 (36) | — |
| Median white-cell count (IQR) — cells/mm3 | 4470 (3850–5480) | 4230–9070 |
| Median lymphocytes (IQR) | ||
| Absolute count — cells/mm3 | 650 (480–880) | 1320–3570 |
| Percentage of white-cell count | 15 (10–21) | 22–53 |
| Median T cells (IQR) — cells/mm3 | ||
| CD3 | 340 (154–565) | 714–2266 |
| CD4 | 80 (25–168) | 359–1565 |
| CD8 | 130 (58–317) | 178–853 |
| CD3+CD4−CD8− | 34 (15–64) | 24–223 |
| Median NK cells (IQR) — cells/mm3 | 142 (100–378) | 126–729 |
| Median B cells (IQR) — cells/mm3 | 144 (92–218) | 61–320 |
| Median immunoglobulin level (IQR) — mg/dl | ||
| IgG | 952 (713–1210) | 700–1600 |
| IgM | 89 (64–136) | 40–230 |
| IgA | 146 (63–196) | 80–350 |
The patients’ demographic characteristics were recorded at the time of enrollment unless otherwise specified (e.g., age at the end of follow-up). The medical history, cell counts, and immunoglobulin levels were recorded between enrollment and the end of follow-up or data censoring on March 2020. IQR denotes interquartile range, and NK natural killer.
Race was reported by the patients.
Autoimmune clinical manifestations were as follows: autoimmune thyroid diseases in 12 patients, sarcoidosis in 5, psoriatic rash in 4, psoriatic arthritis in 2, autoimmune hemolytic anemia in 3, immune thrombocytopenic purpura in 3, ulcerative colitis in 2, vitiligo in 2, discoid lupus in 2, alopecia in 2, systemic lupus erythematosus in 2, atopic dermatitis in 1, ankylosing spondylitis in 1, polyarticular rheumatoid arthritis in 1, autoimmune gastritis in 1, and antiphospholipid syndrome in 1. Patients could have more than one autoimmune condition.